<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0003074'>Hyperglycemia</z:hpo> and Its Effect After <z:hpo ids='HP_0011009'>Acute</z:hpo> <z:hpo ids='HP_0001658'>Myocardial Infarction</z:hpo> on Cardiovascular Outcomes in Patients With Type 2 <z:hpo ids='HP_0000819'>Diabetes Mellitus</z:hpo> (HEART2D) is a multinational, randomized, controlled trial designed to compare the effects of prandial versus fasting glycemic control on risk for cardiovascular outcomes in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> after <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: Patients (type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, aged 30-75 years) were randomly assigned within 21 days after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e> to the 1) prandial strategy (PRANDIAL) (three premeal doses of insulin lispro targeting 2-h postprandial blood <z:chebi fb="105" ids="17234">glucose</z:chebi> &lt;7.5 mmol/l) or the 2) basal strategy (BASAL) (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> twice daily or insulin glargine once daily targeting fasting/premeal blood <z:chebi fb="105" ids="17234">glucose</z:chebi> &lt;6.7 mmol/l) </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: A total of 1,115 patients were randomly assigned (PRANDIAL n = 557; BASAL n = 558), and the mean patient participation after randomization was 963 days (range 1-1,687 days) </plain></SENT>
<SENT sid="3" pm="."><plain>The trial was stopped for lack of efficacy </plain></SENT>
<SENT sid="4" pm="."><plain>Risks of first combined adjudicated primary cardiovascular events in the PRANDIAL (n = 174, 31.2%) and BASAL (n = 181, 32.4%) groups were similar (hazard ratio 0.98 [95% CI 0.8-1.21]) </plain></SENT>
<SENT sid="5" pm="."><plain>Mean A1C did not differ between the PRANDIAL and BASAL groups (7.7 +/- 0.1 vs. 7.8 +/- 0.1%; P = 0.4) during the study </plain></SENT>
<SENT sid="6" pm="."><plain>The PRANDIAL group showed a lower daily mean postprandial blood <z:chebi fb="105" ids="17234">glucose</z:chebi> (7.8 vs. 8.6 mmol/l; P &lt; 0.01) and 2-h postprandial blood <z:chebi fb="105" ids="17234">glucose</z:chebi> excursion (0.1 vs. 1.3 mmol/l; P &lt; 0.001) versus the BASAL group </plain></SENT>
<SENT sid="7" pm="."><plain>The BASAL group showed lower mean fasting blood <z:chebi fb="105" ids="17234">glucose</z:chebi> (7.0 vs. 8.1 mmol/l; P &lt; 0.001) and similar daily fasting/premeal blood <z:chebi fb="105" ids="17234">glucose</z:chebi> (7.7 vs. 7.3 mmol/l; P = 0.233) versus the PRANDIAL group </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Treating diabetic survivors of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e> with prandial versus basal strategies achieved differences in fasting blood <z:chebi fb="105" ids="17234">glucose</z:chebi>, less-than-expected differences in postprandial blood <z:chebi fb="105" ids="17234">glucose</z:chebi>, similar levels of A1C, and no difference in risk for future cardiovascular event rates </plain></SENT>
</text></document>